Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MILOPHENE vs NOLVADEX
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.
NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.
Treatment of metastatic breast cancer in postmenopausal women with estrogen receptor-positive tumors,Reduction in incidence of invasive breast cancer in women at high risk (FDA-approved),Off-label: ovulation induction in anovulatory infertility
Treatment of metastatic breast cancer in women and men,Adjuvant treatment of breast cancer in women with node-positive or node-negative disease following primary surgery,Reduction of breast cancer incidence in high-risk women (pre- and postmenopausal) for primary prevention,Reduction of contralateral breast cancer risk in women with ductal carcinoma in situ (DCIS) or prior breast cancer,Off-label: Induction of ovulation in anovulatory infertility; treatment of gynecomastia; reduction of breast cancer risk in BRCA mutation carriers
1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.
20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.
Terminal elimination half-life is 18-24 hours, supporting once-daily dosing; prolonged in renal impairment.
Tamoxifen: 5-7 days (terminal). N-desmethyltamoxifen (active metabolite): 14 days. Steady-state achieved in 3-4 weeks.
Metabolized primarily by CYP3A4 and CYP2D6 to active metabolites (e.g., N-desmethylmilophene, 4-hydroxymilophene). Undergoes enterohepatic recirculation.
Extensively metabolized in the liver via cytochrome P450 enzymes, primarily CYP2D6 (to active metabolite endoxifen) and CYP3A4, with contributions from CYP2B6, CYP2C9, and CYP2C19. Undergoes glucuronidation and sulfation. Endoxifen is further metabolized by CYP3A4.
Primarily renal excretion of unchanged drug (70-80%), with 10-15% as glucuronide conjugate; biliary/fecal elimination accounts for <10%.
Primarily fecal (65%) as conjugates; renal excretion accounts for approximately 25% as metabolites and <0.5% as unchanged drug. Biliary elimination contributes 10%.
92-96% bound to albumin.
>99% bound primarily to albumin.
0.3-0.4 L/kg, indicating distribution primarily in extracellular fluid.
50-60 L/kg, indicating extensive tissue distribution (e.g., breast, liver, uterus).
Oral: 65-75% with significant first-pass metabolism.
Oral: Approximately 100% after first pass due to extensive hepatic metabolism; absolute bioavailability is nearly complete but variable.
GFR 30-50 m L/min: 75% of normal dose every 6 hours; GFR 15-29 m L/min: 50% of normal dose every 8 hours; GFR <15 m L/min: 25% of normal dose every 12 hours.
No dose adjustment required for mild to moderate renal impairment. For severe renal impairment (Cr Cl <30 m L/min), use with caution; no specific guidelines, consider reduced dose.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: 50% of normal dose every 6 hours; Child-Pugh Class C: contraindicated.
Contraindicated in Child-Pugh class C. For Child-Pugh class B, reduce dose by 50% (e.g., 20 mg every other day). For Child-Pugh class A, no adjustment needed.
Children 1 month to 12 years: 0.5-1 mg/kg intravenously every 4-6 hours, maximum 50 mg per dose; infants <1 month: 0.25-0.5 mg/kg every 6-8 hours.
Safety and efficacy not established in pediatric patients for FDA-approved indications. Off-label use for gonadotropin-independent precocious puberty: 20 mg orally once daily (monitor for potential risks).
Start at 50% of adult dose, increase based on tolerance and renal function; monitor for neurotoxicity and QT prolongation.
No specific dose adjustment recommended based on age alone; dosing same as adults. Monitor for increased risk of thromboembolic events, endometrial cancer, and cataracts. Start at lower end of dosing range (20 mg/day) if frail or with comorbidities.
Boxed Warning: Increased risk of thromboembolic events (deep vein thrombosis, pulmonary embolism) and stroke. Use with caution in patients with history of thromboembolic disorders.
WARNING: SERIOUS AND LIFE-THREATENING EVENTS - NOLVADEX has been associated with an increased risk of uterine malignancies (including endometrial cancer and uterine sarcoma), stroke, and pulmonary embolism. These risks increase with duration of therapy and patient age. Use only when benefit outweighs risk. Educate patients about symptoms of these events and seek prompt medical attention.
Warnings: Thromboembolic events, stroke, endometrial hyperplasia/carcinoma, ovarian cysts, visual disturbances (e.g., cataracts, retinopathy), hepatic impairment, hypercalcemia in bone metastases. Monitor lipid profiles and liver function.
Increased risk of endometrial cancer, uterine sarcoma, and other uterine malignancies; perform baseline gynecologic exam and monitor for abnormal bleeding,Increased risk of thromboembolic events (DVT, PE, stroke); avoid in patients with history of thromboembolism,Hepatotoxicity: elevated liver enzymes, hepatitis, and hepatic steatosis; monitor periodic liver function tests,Ocular effects: cataracts, retinopathy; perform periodic eye exams,Hypercalcemia: may occur in patients with bone metastases; monitor serum calcium,Bone density loss: may cause decreased bone mineral density in premenopausal women; consider calcium and vitamin D supplementation,QT prolongation: use caution with other QT-prolonging drugs or electrolyte imbalances,Fetal harm: can cause fetal harm if used during pregnancy; advise women of childbearing age to use effective contraception
Contraindications: Hypersensitivity to milophene or any component; pregnancy (Category X); history of thromboembolic disease (e.g., DVT, PE); undiagnosed abnormal genital bleeding; hepatic impairment (severe); concurrent use of anticoagulants.
History of deep vein thrombosis (DVT) or pulmonary embolism (PE),History of cerebral vascular accident (CVA) or transient ischemic attack (TIA),Known hypersensitivity to tamoxifen or any component of the formulation,Pregnancy (avoid use unless potential benefit justifies potential risk to fetus); use in women of childbearing age only with adequate contraception,Concurrent use with warfarin or other coumarin-type anticoagulants (relative contraindication due to increased bleeding risk),Severe hepatic impairment (Child-Pugh class C)
Grapefruit juice may increase clomiphene levels; avoid concurrent consumption. No specific food restrictions, but maintain a balanced diet. Limit caffeine intake as it may affect fertility.
Avoid grapefruit and grapefruit juice as they inhibit CYP3A4, potentially altering tamoxifen metabolism. Avoid St. John's wort. No other specific dietary restrictions, but maintain a balanced diet. Alcohol should be limited due to increased risk of liver enzyme elevation.
MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be completely excluded. In the second and third trimesters, continued use may be justified if needed. Limited studies suggest no significant increase in adverse fetal outcomes. However, dopamine agonists have been associated with fetal harm in animal studies, so cautious use is warranted throughout pregnancy.
Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience. First trimester exposure is associated with spontaneous abortions, birth defects (including craniofacial, genital, and skeletal anomalies), and fetal death. Second and third trimester exposure may cause fetal harm including pulmonary hypoplasia and growth retardation. Use is contraindicated during pregnancy.
MILOPHENE is excreted into human breast milk. The M/P ratio is unknown but assumed to be low based on molecular weight and protein binding. Due to potential adverse effects on the infant (e.g., dopamine receptor blockade), breastfeeding is not recommended during therapy. Alternative treatments or cessation of breastfeeding should be considered.
Tamoxifen is excreted in human milk. The milk-to-plasma ratio (M/P) is approximately 0.5-0.75. Due to potential serious adverse reactions in nursing infants, including hormonal effects and carcinogenicity, breastfeeding is not recommended during tamoxifen therapy and for at least 3 months after the last dose.
Pharmacokinetic changes during pregnancy (e.g., increased plasma volume, renal clearance) may require dose adjustment. However, data are limited. Clinical monitoring of prolactin levels and symptom control is recommended. Dose may need to be increased to maintain efficacy, but the lowest effective dose should be used. No specific dose adjustment guidelines exist; therefore, individualized titration based on response is prudent.
Tamoxifen is contraindicated in pregnancy; therefore, dose adjustments are not applicable. If pregnancy occurs during therapy, discontinue tamoxifen immediately and manage with alternative therapies. Pharmacokinetic changes in pregnancy (e.g., increased volume of distribution, altered hepatic metabolism) may reduce tamoxifen exposure, but no dose adjustments have been studied or recommended due to risk.
Milophene (clomiphene citrate) is a selective estrogen receptor modulator used for ovulation induction. Monitor for ovarian hyperstimulation syndrome (OHSS) with pelvic ultrasound. Limit course duration to 6 cycles due to increased risk of ovarian cancer. Use with caution in patients with liver disease or abnormal uterine bleeding. Administer on days 3-7 of menstrual cycle for optimal response.
NOLVADEX (tamoxifen) is a selective estrogen receptor modulator (SERM) indicated for the treatment and prevention of breast cancer. Monitor for endometrial hyperplasia and thromboembolic events. Use with caution in patients with history of DVT/PE. CYP2D6 inhibitors (e.g., paroxetine) reduce conversion to active metabolite endoxifen; avoid coadministration. Tamoxifen can cause tumor flare in bone metastases. Discontinue 2-3 months before attempting pregnancy due to long half-life. Regular gynecologic exams and ophthalmologic monitoring recommended.
Take exactly as prescribed, typically one tablet daily for 5 days starting on cycle day 3, 4, or 5.,Notify your doctor immediately if you experience severe pelvic pain, nausea, vomiting, or sudden weight gain (signs of OHSS).,Avoid pregnancy before starting treatment; use barrier contraception until instructed.,Multiple births (especially twins) occur in about 10% of pregnancies; discuss this risk.,Report any visual disturbances (blurring, spots, flashes) promptly; discontinue use if they occur.,Do not exceed 6 treatment cycles; prolonged use increases ovarian cancer risk.
Take exactly as prescribed; do not skip doses.,Report any unusual vaginal bleeding, pelvic pain, or changes in vision immediately.,Avoid grapefruit juice as it may affect drug levels.,Use effective non-hormonal contraception during therapy and for 2 months after stopping.,Do not take St. John's wort or other herbal supplements without consulting your doctor.,Report leg swelling, chest pain, or shortness of breath promptly.,May cause hot flashes, nausea, or fatigue; these are not reasons to stop without consulting your doctor.,Attend all scheduled gynecologic and eye exams.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MILOPHENE vs NOLVADEX, answered by our medical review team.
MILOPHENE is a Selective Estrogen Receptor Modulator that works by MILOPHENE is a selective estrogen receptor modulator (SERM) that acts as an antagonist in breast tissue and agonist in bone and cardiovascular tissues. It binds competitively to estrogen receptors, inhibiting estrogen-mediated proliferation in breast cancer cells.. NOLVADEX is a Selective Estrogen Receptor Modulator that works by NOLVADEX (tamoxifen citrate) is a nonsteroidal selective estrogen receptor modulator (SERM) that competitively inhibits estrogen binding to estrogen receptors in breast tissue, thereby blocking estrogen-mediated cell proliferation. It also has partial agonist activity in other tissues such as bone and endometrium.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MILOPHENE and NOLVADEX depend on the specific clinical indication. These are both Selective Estrogen Receptor Modulator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MILOPHENE is: 1-2 mg/kg intravenously every 4 hours, not to exceed 100 mg per dose.. The standard adult dose of NOLVADEX is: 20-40 mg orally once daily; for breast cancer, 20 mg/day. For adjuvant therapy, 20 mg/day for 5 years. For ductal carcinoma in situ, 20 mg/day for 5 years. For reduction of breast cancer incidence in high-risk women, 20 mg/day for 5 years.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MILOPHENE and NOLVADEX in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MILOPHENE is classified as Category C. MILOPHENE is a dopamine agonist used for hyperprolactinemia. In the first trimester, there is limited human data but no evidence of increased major malformations. Risk cannot be co. NOLVADEX is classified as Category C. Nolvadex (tamoxifen) is classified as FDA Pregnancy Category D. There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing expe. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.